Alvotech (ALVO) News Today $8.40 +0.25 (+3.07%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$8.41 +0.01 (+0.18%) As of 10/24/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALVO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018 ...1 hour ago | theglobeandmail.comWeiss Ratings Reiterates "Sell (E+)" Rating for Alvotech (NASDAQ:ALVO)October 25 at 3:48 PM | marketbeat.comAlvotech (NASDAQ:ALVO) Lowered to Hold Rating by Zacks ResearchOctober 23 at 7:14 AM | marketbeat.comAlvotech Announces Key Leadership Changes in Commercial OperationsOctober 22, 2025 | tipranks.comAlvotech Announces Key Leadership Changes in Global Business Development and Commercial Operations TeamOctober 22, 2025 | quiverquant.comQAlvotech Announces Leadership Changes in Global Business Development and Commercial Operations TeamOctober 22, 2025 | quiverquant.comQAlvotech Announces Changes in Global Business Development and Commercial Operations TeamOctober 22, 2025 | globenewswire.comAlvotech Announces Changes in Global Business Development and Commercial Operations TeamOctober 22, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Trading Down 1.5% - Here's WhyOctober 21, 2025 | americanbankingnews.comAlvotech (NASDAQ:ALVO) Stock Price Down 1.5% - What's Next?October 21, 2025 | marketbeat.comCould Regulatory Progress on AVT23 Expand Alvotech’s (ALVO) Edge in European Biosimilars?October 17, 2025 | finance.yahoo.comAlvotech (NASDAQ:ALVO) Upgraded at Zacks ResearchOctober 15, 2025 | marketbeat.comAlvotech: Promising Vertically Integrated Biosimilar PlatformOctober 15, 2025 | seekingalpha.comMorgan Stanley Upgrades Alvotech (ALVO)October 14, 2025 | msn.comAlvotech upgraded to Overweight from Equal Weight at Morgan StanleyOctober 14, 2025 | msn.comAlvotech (NASDAQ:ALVO) Shares Gap Up - Here's WhyOctober 14, 2025 | marketbeat.comAlvotech's (ALVO) Sell (E+) Rating Reiterated at Weiss RatingsOctober 8, 2025 | marketbeat.comAlvotech’s AVT23 Biosimilar Gains EMA AcceptanceOctober 6, 2025 | tipranks.comAdvanz Pharma and Alvotech Announce EMA Acceptance of Marketing Authorization Application for Biosimilar AVT23October 6, 2025 | quiverquant.comQAdvanz Pharma and Alvotech Announce EMA Acceptance of Marketing Application for Biosimilar AVT23 to Xolair®October 6, 2025 | quiverquant.comQEuropean Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines AgencyOctober 6, 2025 | globenewswire.comEuropean Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines AgencyOctober 6, 2025 | globenewswire.comA Fresh Look at Alvotech (NasdaqGM:ALVO) Valuation After Recent Stock UptickOctober 3, 2025 | finance.yahoo.comEMA Greenlights for Key Biosimilars Might Change the Case for Investing in Alvotech (ALVO)October 2, 2025 | finance.yahoo.comAlvotech upgraded to “buy” by Deutsche Bank as biosimilar launches boost outlookSeptember 24, 2025 | investing.comAlvotech jumps as Deutsche Bank lifts to Buy on ’material thematic opportunity’September 23, 2025 | investing.comAlvotech rises 12.9%September 23, 2025 | msn.comAlvotech (NASDAQ:ALVO) Shares Gap Up Following Analyst UpgradeSeptember 23, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Upgraded to Buy at Deutsche Bank AktiengesellschaftSeptember 23, 2025 | marketbeat.comAlvotech says CHMP adopts positive opinion for AVT03September 22, 2025 | msn.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | markets.businessinsider.comEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | markets.businessinsider.comAlvotech Gains Key Approvals for Biosimilars in Japan and EuropeSeptember 22, 2025 | tipranks.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | globenewswire.comEuropean Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®September 22, 2025 | globenewswire.comAlvotech and Advanz Pharma Announce Positive CHMP Opinion for Gobivaz® Biosimilar in EuropeSeptember 22, 2025 | quiverquant.comQAlvotech and Advanz Pharma Announce Positive EMA Opinion for Gobivaz®, a Biosimilar to Simponi®September 22, 2025 | quiverquant.comQEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | globenewswire.comEuropean Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization PartnerSeptember 22, 2025 | globenewswire.comAlvotech announces marketing approval in Japan for three biosimilarsSeptember 20, 2025 | msn.comAlvotech gets marketing approval in Japan for three new biosimilarsSeptember 19, 2025 | seekingalpha.comAlvotech and Fuji Pharma Receive Approval for Three New Biosimilars in JapanSeptember 19, 2025 | quiverquant.comQAlvotech and Fuji Pharma Announce Marketing Approval for Three New Biosimilars in JapanSeptember 19, 2025 | quiverquant.comQAlvotech Announces Marketing Approval in Japan of Three New BiosimilarsSeptember 19, 2025 | globenewswire.comAlvotech Announces Marketing Approval in Japan of Three New BiosimilarsSeptember 19, 2025 | globenewswire.comAlvotech (NASDAQ:ALVO) Sees Large Drop in Short InterestSeptember 17, 2025 | marketbeat.comAlvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comPointState Capital LP Cuts Stake in Alvotech $ALVOSeptember 8, 2025 | marketbeat.comAlvotech (NASDAQ:ALVO) Short Interest UpdateSeptember 8, 2025 | marketbeat.comAlvotech to Present at Morgan Stanley 23rd Annual Global Healthcare Conference in New YorkSeptember 4, 2025 | quiverquant.comQ Get Alvotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALVO Media Mentions By Week ALVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALVO News Sentiment▼0.480.84▲Average Medical News Sentiment ALVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALVO Articles This Week▼126▲ALVO Articles Average Week Get the Latest News and Ratings for ALVO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Alvotech and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies BBIO News Today MRNA News Today RVMD News Today VRNA News Today RYTM News Today ABVX News Today MRUS News Today RNA News Today CYTK News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALVO) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredTrade this between 9:30 and 10:45 am ESTIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alvotech Please log in to your account or sign up in order to add this asset to your watchlist. Share Alvotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
